Table Info

Table 1.

Several clinical trials are currently underway to this investigate

Type	Study	Design	Population	Explorimental arm	ORR	DCR	mPFS (m)	OS (m)	AE/TEAE	Reference
ICIs monotherapy	JAVELIN	1b, open label	n = 125	Ave	9.6%		10.2% (y = 1)	11.2	7.2% pts, 3–4 S	[41]
	KEYNOTE-028	Age ≥ 18 y, advanced, PD-L1 positivity	n = 26	Pembrolizumab	11.5%		1.9 m	13.8	19 (73.1%) pts, one grade 3 S	[44]
	KEYNOTE-100	Phase II	Cohort A, n = 285 Cohort A, n = 91	Pembrlizumab	A 7.4% B 9.9% CPS+ < 1 was 4.1% > 1 was 5.7% ≥ 10 was 10.0%	A: 8.2 m B: not reached	2.1 m	A: not reached B: 17.6		[45]
	NANT study	Prospective, multicenter, phase II, single arm	n = 127, HRD pts n = 67	Niraparibb	HRD pts: 62.5% BRCAm pts: 77.3%	HRD pts: 87.5% BRCAm pts: 100%			≥ 3 S	[97]
Chemotherapy plus ICIs	JAVELIN-200	An open-label, three-arm, randomized, phase 3	n = 566	Ave:Ave + PLD:PLD = 1:1:1			Ave: 9 m Ave + PLD: 3.7 m PLD: 3.5 m	Ave: 8.2 Ave + PLD: 18.4 PLD: 17.4	≥ 3 S	[53]
	JAVELIN-100	Global, open label, three-arm, parallel, randomized, phase 3	Ave: n = 332 Chemotherapy + Ave: n = 331 Control: n = 335	Ave:chemotherapy + Ave:control = 1:1:1			Ave: 16.8 m Chemotherapy + Ave: 18.1 m Control: NE	Interruption		[54]
	Combined pembrolizumab and PLD in PROC	Single arm, multi-center phase II	n = 26	PLD + pembrolizumab	26.1%					[55]
Anti-angiogenic drugs plus ICIs	Assessment of combined Niv and Bev in ROC	Single-arm, phase 2	n = 38 PROC: n = 18 PSOC: n = 20	Niv + Bev	PROC: 16.7% PSOC: 40.0%		8.1 m		≥ 3 S	[71]
Anti-angiogenic drugs plus ICIs	ATALANTE/ENGOT-ov29	Randomized (2:1), double blinded, phase III, PSOC	n = 614 Atezolizumab: n = 410 Placebo: n = 204	Cx + Bev + At; Cx + Bev + placebo			At: 13.5 m Placebo: 11.3 m PD-L1-positive: 15.2 m vs. 13.1 m	At: 35.5 m Placebo: 30.6 m	≥ 3 S	[98]
PARP inhibitors plus ICIs	MEDIOLA	Multicenter, open-label, phase 1/2, basket trial	gBRCAm doublet: n = 51 Non-gBRCAm doublet: n = 32 Non-gBRCAm triplet cohorts: n = 31	Olaparib plus durvalumab, with or without Bev	gBRCAm expansion doublet 92.2%	(at 24 weeks) non-gBRCAm doublet: 28.1% Non-gBRCAm triplet cohorts: 74.2%			≥ 3 S	[81, 99]
PARP inhibitors plus ICIs	Keynote-162	Open-label, single-arm phases 1 and 2 study	n = 62	Niraparib + pembrolizumab	18%	65%	3 m		≥ 3 S	[100, 101]
ADCs plus ICIs	FORWARDII	Ib	MIRV + pembrolizumab	43%	mDOR 6.9 m		5.2 m			[80]
PD-1 + CTLA-4	NGR oncology study	Randomized phase II	Niv (n = 49) Niv and ipilimumab (n = 51)	Niv and ipilimumab	Niv: 12.2 m Niv and ipilimumab: 31.4 m		Niv: 2 m Niv + ipilimumab: 3.9 m		≥ 3 S Niv: 3% Niv + ipilimumab: 49%	[88]
Anti-CD27 antibody + anti-PD-1	Agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (Niv)	Phase 1/2 dose-escalation and expansion	n = 175 (phase 1 n = 36; phase 2 n = 139)	Varlilumab and Niv	Phase 1: uncertain Phase 2: 12.5%				Without significant toxicity	[90]

pts: patients; PD-L1: programmed cell death ligand 1; mPFS: median progression-free survival; ORR: objective response rate; OS: overall survival; mOS: median OS; DCR: disease control rate; mDOR: median duration of response; AE: adverse event; TRAEs: treatment-related AEs; n: number; PSOC: platinum-sensitive recurrent ovarian cancer; PROC: platinum-resistant recurrent ovarian cancer; Cx: platinum-based chemotherapy; Bev: bevacizumab; MIRV: mirvetuximab soravtansine; ADCs: antibody-drug conjugates; ICIs: immune checkpoint inhibitors; GEM/PLD: gemcitabine or pegylated liposomal doxorubicin; Ave: avelumab; Niv: nivolumab; m: months; y: years; CPS: combined positive score; NE: not evaluated; CTLA-4: cytotoxic T-lymphocyte antigen 4; PD-1: programmed cell death protein 1; HRD: homologous recombination deficiency; BRCAm: BRCA mutated; gBRCAm: germline BRCAm

Declarations

Author contributions

GN: Writing—review & editing, Conceptualization. LZ: Writing—original draft, Investigation, Conceptualization. YZ: Data curation.

Conflicts of interest

We declare that we have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This study was financially supported by grants from Science and Technology Tackling in Henan Province [242102310359]; and Henan Polytechnic University Youth Innovation Exploratory Fund [NSFRF230414]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584–90. [DOI] [PubMed] [PMC]

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. [DOI] [PubMed]

Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022;86:207–23. [DOI] [PubMed]

Nespolo A, Stefenatti L, Pellarin I, Gambelli A, Rampioni Vinciguerra GL, Karimbayli J, et al. USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity. Sci Adv. 2024;10:eadp6567. [DOI] [PubMed] [PMC]

Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. [DOI] [PubMed]

Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203–23. [DOI] [PubMed]

Xiao F, Wang Z, Qiao L, Zhang X, Wu N, Wang J, et al. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer. J Transl Med. 2024;22:778. [DOI] [PubMed] [PMC]

Zhao Q, Bai L, Tan Y, Qie M. Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer. Front Oncol. 2024;14:1435029. [DOI] [PubMed] [PMC]

Malik S, Sikander M, Bell N, Zubieta D, Bell MC, Yallapu MM, et al. Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy. J Ovarian Res. 2024;17:161. [DOI] [PubMed] [PMC]

10.

Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010;2010:932371. [DOI] [PubMed] [PMC]

11.

Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44. [DOI] [PubMed] [PMC]

12.

Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci. 2021;22:6532. [DOI] [PubMed] [PMC]

13.

Emmanuelli A, Salvagno C, Hwang SM, Awasthi D, Sandoval TA, Chae CS, et al. High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils. Oncoimmunology. 2024;13:2411070. [DOI] [PubMed] [PMC]

14.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13. [DOI] [PubMed]

15.

Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature. 2022;612:778–86. [DOI] [PubMed] [PMC]

16.

Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002–14. [DOI] [PubMed]

17.

Han YL, Fang Z, Gao ZJ, Li WG, Yang J. Comprehensive single-cell and bulk RNA-seq analyses reveal a novel CD8⁺T cell-associated prognostic signature in ovarian cancer. Aging (Albany NY). 2024;16:10636–56. [DOI] [PubMed] [PMC]

18.

Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929–38. [DOI] [PubMed]

19.

Wang ZB, Zhang X, Fang C, Liu XT, Liao QJ, Wu N, et al. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology. 2024;173:14–32. [DOI] [PubMed]

20.

Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124:192–8. [DOI] [PubMed] [PMC]

21.

Wang X, Li X, Wei L, Yu Y, Hazaisihan Y, Tao L, et al. Acetylation model predicts prognosis of patients and affects immune microenvironment infiltration in epithelial ovarian carcinoma. J Ovarian Res. 2024;17:150. [DOI] [PubMed] [PMC]

22.

Satora M, Kułak K, Zaremba B, Grunwald A, Świechowska-Starek P, Tarkowski R. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment-a narrative review. Front Pharmacol. 2024;15:1416555. [DOI] [PubMed] [PMC]

23.

Mateiou C, Lokhande L, Diep LH, Knulst M, Carlsson E, Ek S, et al. Spatial tumor immune microenvironment phenotypes in ovarian cancer. NPJ Precis Oncol. 2024;8:148. [DOI] [PubMed] [PMC]

24.

Niu G, Wang H, Zhai Y, Zhou B, Kang Y, Pei Z, et al. Nanotechnology-based in situ cancer vaccines: Mechanisms, design, and recent advances. Nano Today. 2024;56:102286. [DOI]

25.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. [DOI] [PubMed]

26.

Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28:viii1–7. [DOI] [PubMed] [PMC]

27.

Colombo I, Karakasis K, Suku S, Oza AM. Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery. Cancers (Basel). 2023;15:3220. [DOI] [PubMed] [PMC]

28.

Zhao J, Wang Z, Tian Y, Ning J, Ye H. T cell exhaustion and senescence for ovarian cancer immunotherapy. Semin Cancer Biol. 2024;104-105:1–15. [DOI] [PubMed]

29.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. [DOI] [PubMed] [PMC]

30.

Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, et al. CD4⁺T cell-induced inflammatory cell death controls immune-evasive tumours. Nature. 2023;618:1033–40. [DOI] [PubMed] [PMC]

31.

Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther. 2008;8:243–57. [DOI] [PubMed]

32.

Emens LA, Kok M, Ojalvo LS. Targeting the programmed cell death-1 pathway in breast and ovarian cancer. Curr Opin Obstet Gynecol. 2016;28:142–7. [DOI] [PubMed]

33.

Chen J, Yang L, Ma Y, Zhang Y. Recent advances in understanding the immune microenvironment in ovarian cancer. Front Immunol. 2024;15:1412328. [DOI] [PubMed] [PMC]

34.

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104:3360–5. [DOI] [PubMed] [PMC]

35.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375:819–29. [DOI] [PubMed] [PMC]

36.

Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017;14:662–74. [DOI] [PubMed] [PMC]

37.

Gottlieb CE, Mills AM, Cross JV, Ring KL. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. Gynecol Oncol. 2017;144:607–12. [DOI] [PubMed]

38.

Reddy SU, Sadia FZ, Vancura A, Vancurova I. IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance. Cancers (Basel). 2024;16:2676. [DOI] [PubMed] [PMC]

39.

Huang Y, Chen Z, Shen G, Fang S, Zheng J, Chi Z, et al. Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis. Hum Vaccin Immunother. 2024;20:2318815. [DOI] [PubMed]

40.

Szamreta EA, Li Y, Monberg MJ, Othus M. Long-term survival in newly-diagnosed ovarian cancer patients. J Clin Oncol. 2022;40:e17543. [DOI]

41.

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5:393–401. [DOI] [PubMed] [PMC]

42.

Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019;154:314–22. [DOI] [PubMed]

43.

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015;33:4015–22. [DOI] [PubMed]

44.

Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol Oncol. 2019;152:243–50. [DOI]

45.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30:1080–7. [DOI] [PubMed]

46.

Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226. [DOI] [PubMed] [PMC]

47.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. [DOI] [PubMed] [PMC]

48.

Zhao Y, Wang C, Deng W, Li L, Liu J, Shi Y, et al. Patient-derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin. MedComm (2020). 2024;5:e697. [DOI] [PubMed] [PMC]

49.

Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat Genet. 2020;52:582–93. [DOI] [PubMed] [PMC]

50.

Spagnol G, Ghisoni E, Morotti M, De Tommasi O, Marchetti M, Bigardi S, et al. The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature. Int J Mol Sci. 2024;25:7070. [DOI] [PubMed] [PMC]

51.

Leary A, Genestie C, Blanc-Durand F, Gouy S, Dunant A, Maulard A, et al. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. Cancer Immunol Immunother. 2021;70:519–31. [DOI] [PubMed] [PMC]

52.

Jlassi A, Rejaibi R, Manai M, Sahraoui G, Guerfali FZ, Charfi L, et al. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma. Front Oncol. 2024;14:1352053. [DOI] [PubMed] [PMC]

53.

Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22:1034–46. [DOI] [PubMed]

54.

Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:1275–89. [DOI] [PubMed]

55.

Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020;159:72–8. [DOI]

56.

Ray-Coquard IL, Savoye AM, Schiffler C, Mouret-Reynier MA, Derbel O, Kalbacher E, et al. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nat Commun. 2024;15:5931. [DOI] [PubMed] [PMC]

57.

Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺T cells. Cancer Cell. 2024;42:1582–97.e10. [DOI] [PubMed] [PMC]

58.

Zhang R, Yao Y, Gao H, Hu X. Mechanisms of angiogenesis in tumour. Front Oncol. 2024;14:1359069. [DOI] [PubMed] [PMC]

59.

Guo M, Ying Y, Chen Y, Miao X, Yu Z. Asiaticoside inhibits breast cancer progression and tumor angiogenesis via YAP1/VEGFA signal pathway. Heliyon. 2024;10:e37169. [DOI] [PubMed] [PMC]

60.

Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y, et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer. 2021;20:7. [DOI] [PubMed] [PMC]

61.

Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250–4. [DOI] [PubMed] [PMC]

62.

Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, et al. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2021;7:78–85. [DOI] [PubMed] [PMC]

63.

Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, et al. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16:94. [DOI] [PubMed] [PMC]

64.

Han Z, Dong Y, Lu J, Yang F, Zheng Y, Yang H. Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application. Am J Cancer Res. 2021;11:3777–93. [PubMed] [PMC]

65.

Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017;9:289–302. [DOI] [PubMed] [PMC]

66.

Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019;12:98. [DOI] [PubMed] [PMC]

67.

van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024;42:1032–50.e10. [DOI] [PubMed]

68.

Wu S, Zhang X, Hu C, Zhong Y, Chen J, Chong WP. CD8⁺T cells reduce neuroretina inflammation in mouse by regulating autoreactive Th1 and Th17 cells through IFN-γ. Eur J Immunol. 2023;53:e2350574. [DOI] [PubMed]

69.

Lin Z, Zou S, Wen K. The crosstalk of CD8+ T cells and ferroptosis in cancer. Front Immunol. 2024;14:1255443. [DOI] [PubMed] [PMC]

70.

Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475–85. [DOI] [PubMed] [PMC]

71.

Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, et al. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5:1731–8. [DOI] [PubMed] [PMC]

72.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women’s Cancers: A Dose-Escalation, Phase I Study. J Clin Oncol. 2017;35:2193–202. [DOI] [PubMed] [PMC]

73.

Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39:1842–55. [DOI] [PubMed] [PMC]

74.

Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, et al.; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023;41:4768–78. [DOI] [PubMed] [PMC]

75.

Richardson DL, Barve MA, Strauss JF, Ulahannan SV, Moore KN, Hamilton EP, et al. Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38:3549. [DOI]

76.

Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641–61. [DOI] [PubMed]

77.

Wang AJ, Gao Y, Shi YY, Dai MY, Cai HB. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer. Front Pharmacol. 2022;13:1093666. [DOI] [PubMed] [PMC]

78.

Nicolò E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395. [DOI] [PubMed]

79.

Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther. 2022;236:108106. [DOI] [PubMed]

80.

Gonzalez-Ochoa E, Veneziani AC, Oza AM. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. Clin Med Insights Oncol. 2023;17:11795549231187264. [DOI] [PubMed] [PMC]

81.

Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155–64. [DOI] [PubMed]

82.

Karpel HC, Powell SS, Pothuri B. Antibody-Drug Conjugates in Gynecologic Cancer. Am Soc Clin Oncol Educ Book. 2023;43:e390772. [DOI] [PubMed]

83.

Sharma M, Carvajal RD, Hanna GJ, Bob M, Moore KN, Pegram M, et al. Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. J Clin Oncol. 2021;39:2549. [DOI]

84.

Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17:54. [DOI] [PubMed] [PMC]

85.

Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67. [DOI] [PubMed] [PMC]

86.

Blanc-Durand F, Clemence Wei Xian L, Tan DSP. Targeting the immune microenvironment for ovarian cancer therapy. Front Immunol. 2023;14:1328651. [DOI] [PubMed] [PMC]

87.

Galle P, Finn RS, Mitchell CR, Ndirangu K, Ramji Z, Redhead GS, et al. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review. J Immunother Cancer. 2024;12:e008266. [DOI] [PubMed] [PMC]

88.

Zamarin D, Burger RA, Sill MW, Powell DJ Jr, Lankes HA, Feldman MD, et al. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol. 2020;38:1814–23. [DOI] [PubMed] [PMC]

89.

Ansell SM, Flinn I, Taylor MH, Sikic BI, Brody J, Nemunaitis J, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020;4:1917–26. [DOI] [PubMed] [PMC]

90.

Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, et al. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer. 2022;10:e005147. [DOI] [PubMed] [PMC]

91.

Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, et al. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J Clin Oncol. 2021;39:3671–81. [DOI] [PubMed] [PMC]

92.

Garlisi B, Lauks S, Aitken C, Ogilvie LM, Lockington C, Petrik D, et al. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities. Curr Oncol. 2024;31:3826–44. [DOI] [PubMed] [PMC]

93.

Chen Y, Liu X, Hu Y, Xia L. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2024;103:e38019. [DOI] [PubMed] [PMC]

94.

Pawłowska A, Rekowska A, Kuryło W, Pańczyszyn A, Kotarski J, Wertel I. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. Int J Mol Sci. 2023;24:10859. [DOI] [PubMed] [PMC]

95.

Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15:61. [DOI] [PubMed] [PMC]

96.

McCloskey CW, Rodriguez GM, Galpin KJC, Vanderhyden BC. Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. Cancers (Basel). 2018;10:244. [DOI] [PubMed] [PMC]

97.

Gao Q, Liu D, Li H, Zhang W, Wang P, Li J, et al. Efficacy, safety, and biomarkers of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD) advanced ovarian cancer: A prospective, multicenter, phase II, single-arm NANT study. J Clin Oncol. 2024;42:5549. [DOI]

98.

Kurtz JE, Marth C, Oaknin A, Asselain B, Baumann KH, Cibula D, et al. ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab. J Clin Oncol. 2018;36:TPS5607. [DOI]

99.

Drew Y, Kim JW, Penson RT, O’Malley DM, Parkinson C, Roxburgh P, et al.; MEDIOLA Investigators. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin Cancer Res. 2024;30:50–62. [DOI] [PubMed] [PMC]

100.

Konstantinopoulos PA, Waggoner SE, Vidal GA, Mita MM, Fleming GF, Holloway RW, et al. TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. J Clin Oncol. 2018;36:106. [DOI]

101.

Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019;5:1141–9. [DOI] [PubMed] [PMC]